Literature DB >> 28687404

Significant reduction in notification and seroprevalence rates of hepatitis B virus infection among the population of Zhejiang Province, China, aged between 1 and 29years from 2006 to 2014.

Yang Zhou1, Hanqing He2, Xuan Deng3, Rui Yan4, Xuewen Tang5, Shuyun Xie6, Jun Yao7.   

Abstract

BACKGROUND AND
OBJECTIVE: The Chinese government integrated hepatitis B vaccination into the national immunization program in 1992, when the hepatitis B birth dose was introduced in China. Zhejiang province is a relatively developed area in eastern China and was an area with high endemicity for hepatitis B virus (HBV) infection via mother-to-child transmission. The hepatitis B vaccine vaccination rates for the birth dose and 3- dose schedule in Zhejiang Province since 1992 have both remained above 90% [1]. The results of two hepatitis B seroepidemiological surveys conducted in 2006 and 2014, respectively, to evaluate the rates of notification and seroprevalence of HBV infection among the population of Zhejiang Province, China, aged between 1 and 29years.
METHODS: Data on the notification rates of HBV infection in Zhejiang province from 2006 to 2014 were obtained from the National Notifiable Disease Reporting System (NNDRS). The prevalence rate of HBV serological markers and the rate of immunization coverage were compared between surveys.
RESULTS: The reported notification rates in people aged between 1 and 29years according to the NNDRS decreased approximately 4.88 times from 2006 to 2014. The prevalence of HBsAg decreased from 2.16% in 2006 to 1.05% in 2014, while the prevalence of anti-HBc decreased from 7.13% to 5.49%. The anti-HBc seroprevalence in the 15-29-year-old age group was significantly higher than that in all the other age groups both in the 2006 and 2014 serosurveys. The rate of anti-HBs seroprevalence in those aged between 1 and 14years was maintained at a high level between 2006 and 2014.
CONCLUSIONS: The rate of hepatitis B reported and the rate of HBsAg positivity decreased significantly in Zhejiang province by maintaining the high-level coverage rate of the hepatitis B timely birth dose and three-dose schedule. While additional efforts are needed to achieve the goal of elimination.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hepatitis B; Seroprevalence; Vaccination; Vaccine coverage

Mesh:

Substances:

Year:  2017        PMID: 28687404     DOI: 10.1016/j.vaccine.2017.06.078

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China.

Authors:  Yanbing Zeng; Mingliang Luo; Jianlin Lin; Hanqing He; Xuan Deng; Shuyun Xie; Ya Fang
Journal:  Hum Vaccin Immunother       Date:  2019-11-26       Impact factor: 3.452

2.  The effect of hepatitis B vaccination after five years on an entire population in an insular region of Southeast China.

Authors:  Ying Liu; Jingjing Ren; Zikang Wu; Lingzhi Shen; Huan Shan; Xuewei Dai; Jing Li; Yan Qiu; Wen Ren; Jun Yao; Lanjuan Li
Journal:  Hum Vaccin Immunother       Date:  2020-12-14       Impact factor: 3.452

Review 3.  Revaccination against hepatitis B in late teenagers who received vaccination during infancy: Yes or no?

Authors:  Hong Zhao; Yi-Hua Zhou
Journal:  Hum Vaccin Immunother       Date:  2017-12-06       Impact factor: 3.452

4.  Anti-HBs levels in children under the age of two years born to HBV carrier mothers after immunoprophylaxis: a multicenter cross-sectional study.

Authors:  Min Jiang; Bo Zhu; Qiang Yao; Haifeng Lou; Xiaohui Zhang
Journal:  BMC Pediatr       Date:  2021-11-04       Impact factor: 2.125

5.  Analysis of epidemiological serosurvey of hepatitis B virus among people under 29 years of age in Jiangsu Province, China.

Authors:  Xiang Sun; Yuanyuan Zhu; Fenyang Tang; Xiuying Deng; Zhiguo Wang; Yuanbao Liu
Journal:  Hum Vaccin Immunother       Date:  2021-06-07       Impact factor: 4.526

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.